Mackay Shields LLC Invests $13.18 Million in Baxter International Inc (BAX) Stock

Mackay Shields LLC acquired a new stake in Baxter International Inc (NYSE:BAX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 200,240 shares of the medical instruments supplier’s stock, valued at approximately $13,180,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Gantzert Investment Co. LLC ADV acquired a new stake in shares of Baxter International during the fourth quarter worth $25,000. Parisi Gray Wealth Management acquired a new stake in shares of Baxter International during the fourth quarter worth $26,000. Baldwin Brothers Inc. MA boosted its holdings in shares of Baxter International by 904.0% during the fourth quarter. Baldwin Brothers Inc. MA now owns 502 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 452 shares during the last quarter. We Are One Seven LLC acquired a new stake in shares of Baxter International during the fourth quarter worth $34,000. Finally, Financial Gravity Companies Inc. acquired a new stake in shares of Baxter International during the fourth quarter worth $45,000. 81.39% of the stock is owned by hedge funds and other institutional investors.

NYSE:BAX opened at $76.94 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.50 and a current ratio of 2.09. Baxter International Inc has a 12 month low of $61.05 and a 12 month high of $78.38. The stock has a market capitalization of $39.43 billion, a price-to-earnings ratio of 25.23, a P/E/G ratio of 1.90 and a beta of 1.00.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, January 31st. The medical instruments supplier reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Baxter International had a return on equity of 19.10% and a net margin of 14.60%. The company had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.80 billion. Equities research analysts anticipate that Baxter International Inc will post 3.27 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Shareholders of record on Friday, March 1st will be given a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.99%. The ex-dividend date is Thursday, February 28th. Baxter International’s dividend payout ratio (DPR) is presently 24.92%.

In other Baxter International news, SVP Jeanne K. Mason sold 37,274 shares of the firm’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $72.00, for a total value of $2,683,728.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Thomas T. Stallkamp sold 3,187 shares of the firm’s stock in a transaction dated Friday, January 18th. The shares were sold at an average price of $70.00, for a total value of $223,090.00. Following the completion of the transaction, the director now directly owns 9,418 shares in the company, valued at $659,260. The disclosure for this sale can be found here. Insiders sold 44,599 shares of company stock worth $3,216,661 over the last three months. 0.07% of the stock is currently owned by corporate insiders.

Several brokerages recently weighed in on BAX. Zacks Investment Research lowered Baxter International from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Citigroup raised Baxter International from a “neutral” rating to a “buy” rating and increased their target price for the stock from $69.00 to $76.00 in a research report on Wednesday, January 2nd. Credit Suisse Group began coverage on Baxter International in a research report on Monday, December 17th. They issued an “outperform” rating and a $77.00 target price on the stock. Barclays raised Baxter International from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $67.00 to $72.00 in a research report on Friday, February 1st. Finally, UBS Group began coverage on Baxter International in a research report on Tuesday, November 27th. They issued a “buy” rating and a $80.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $76.56.

TRADEMARK VIOLATION NOTICE: This report was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another publication, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this report can be read at https://transcriptdaily.com/2019/03/17/mackay-shields-llc-invests-13-18-million-in-baxter-international-inc-bax-stock.html.

Baxter International Company Profile

Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: What type of investment options does a Roth IRA provide?

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.